Judges Scientific PLC

-7.19%

Judges Scientific has suffered a dramatic reversal. On October 13, 2026, shares closed at 3,550 pence, approximately 42% below their 52-week high of 6,100 pence. For investors who once admired its acquisition-driven growth, the big question is whether this decline creates a genuine value opportunity or signals deeper trouble. The first half of 2026 was exceptionally difficult. Revenue fell 21% to £55.7 million, while adjusted profit before tax plunged 75% to £3.2 million. Earnings per share dropped from 141.4 pence to 39 pence. Reduced United States research funding, delays in China and weakness in offshore wind weighed on demand. There are reasons for cautious optimism. Management maintained its full-year expectations, reporting that order intake improved during the early part of the second half. The company also raised its interim dividend by 10% to 36 pence. Total annual dividends increased from 95 pence in 2023 to 104.5 pence in 2024 and 115 pence in 2025. A recovery could follow if orders translate into revenue and margins improve. However, weak research budgets, delayed projects, leadership changes and a prolonged downturn remain significant risks. The lower valuation may offer an opportunity, but earnings recovery is essential to justify renewed investor confidence. This review is for informational and educational purposes only, not financial advice.

A concise review of Judges Scientific PLC: company overview, financials, stock pressures, dividends, risks, and value-analysis insights. Educational only.

Judges Scientific, a UK-based scientific instrument group, has seen its stock price slide despite steady financials and a smart acquisition strategy. We break down the data and assess the value potential.